- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02620397
Clinical Study to Validate the Use of a New Point of Care Troponin I Test
Clinical Study to Validate the Use of a New Point of Care Troponin I Test as an Aid in the Diagnosis of Myocardial Infarction and Prognosis of Subjects Presenting With Symptoms of Acute Coronary Syndrome
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
This trial is designed as a prospective, multi-center, observational study of "all-comers" eligible adult subjects presenting to participating Emergency Departments (EDs) with symptoms suggestive of ACS and/or myocardial ischemia. Subjects presenting with symptoms suggestive of ACS will be screened and approached for consent for study enrollment by trained personnel.
After obtaining written informed consent, subjects will have up to 4 blood samples collected for cTnI testing using the Meritas Troponin I test and Meritas point-of-care (POC) Analyzer. Blood draws and testing will occur at 4 intervals over 24 hours.
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiesteder
-
-
California
-
San Francisco, California, Forenede Stater, 94110
- San Francisco General Hospital & Trauma Center
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32608
- University of Florida
-
-
Idaho
-
Idaho Falls, Idaho, Forenede Stater, 83404
- Eastern Idaho Regional Medical Center
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40202
- University of Louisville
-
Louisville, Kentucky, Forenede Stater, 40202
- Kentucky Clinical Trials Laboratories
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- University of Maryland
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55404
- Hennepin County Medical Ctr
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89109
- Sunrise Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28293
- Carolinas Medical Center
-
Greenville, North Carolina, Forenede Stater, 27834
- East Carolina University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Thomas Jefferson Univeristy
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37232
- Vanderbilt University
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Ben Taub
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- The informed consent must be signed by the subject, or the subject's legal authorized representative.
- 21 years of age or greater at the time of enrollment
- Subjects presenting to the ED with any symptoms suggestive of ACS and/or myocardial ischemia, such as but not limited to: subjects currently having chest pain, pressure or a burning sensation across the precordium and epigastrium, pain that radiates to neck, shoulder, jaw, back, upper abdomen and either arm.
Exclusion Criteria:
- Informed consent form not signed
- Age <21 years
- Known pregnancy -
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical performance of the Meritas Troponin I test
Tidsramme: 24-hours
|
Clinical performance indicators (Sensitivity, Specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) and their respective 95 % confidence intervals (CIs) will be calculated for the quantitative determination of cardiac troponin I (cTnI) for use as an aid in the diagnosis of myocardial infarction (MI)
|
24-hours
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Prognostic capability of sponsor's Meritas Troponin I to predict mortality (all-cause death) and cardiac events (i.e., MI, cardiac death).
Tidsramme: 1 year
|
Kaplan-Meier survival curves and risk ratios.
A multivariate Cox proportional model with known risk factors as covariates in addition to the Troponin test result will be included in the data analysis
|
1 year
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Jim Rock, Trinity Biotech
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CP7001_5ACS
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Akut koronarsyndrom
-
IRCCS Policlinico S. DonatoRekrutteringAnomalous aorta origin of the coronary artery (AAOCA)Italien
-
IRCCS Policlinico S. DonatoUniversity of Pavia; University of Naples; The Mediterranean Institute for...RekrutteringMyokardieiskæmi | Pludselig hjertedød | Anomal koronararterieoprindelse | Anomal koronararterie, der opstår fra den modsatte sinus | Anomal koronararterie med aorta-oprindelse og forløb mellem de store arterier | Anomalous aorta origin of the coronary artery (AAOCA) | Myokardieiskæmi, Angina Pectoris og andre forholdItalien
-
GlaxoSmithKlineIkke rekrutterer endnu
-
Helen Keller Eye Research FoundationFive Lakes Clinical Research Consulting, LLCRekrutteringStickler syndrom type 2 | Stickler syndrom type 1Forenede Stater
-
Unravel Biosciences, Inc.RekrutteringPitt Hopkins syndromColombia
-
University of California, Los AngelesBoston Children's Hospital; Duke University; Children's Hospital Medical...RekrutteringBohring-Opitz syndrom | ASXL1 genmutation | Shashi-Pena syndrom | ASXL2-genmutation | Bainbridge-Ropers syndrom | ASXL3 genmutationForenede Stater
-
Neuren Pharmaceuticals LimitedRekrutteringPhelan-McDermid syndromForenede Stater
-
Neuren Pharmaceuticals LimitedRekrutteringPhelan-McDermid syndromForenede Stater
-
University of California, DavisNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AfsluttetTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapi-relateret myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært højrisiko myelodysplastisk syndromForenede Stater
-
Riphah International UniversityAfsluttet